Cancer-drug setback sends Merck shares down again

NEW YORK (Reuters) – A setback for Merck & Co’s key cancer drug sent the drugmaker’s stock swooning on Monday for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *